0001209191-20-016348.txt : 20200304 0001209191-20-016348.hdr.sgml : 20200304 20200304185303 ACCESSION NUMBER: 0001209191-20-016348 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200302 FILED AS OF DATE: 20200304 DATE AS OF CHANGE: 20200304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Campbell Bradley L CENTRAL INDEX KEY: 0001400971 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 20688941 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-02 0 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001400971 Campbell Bradley L C/O AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE CRANBURY NJ 08512 1 1 0 0 Chief Operating Officer Common Stock 2020-03-02 4 M 0 7500 5.96 A 370517 D Common Stock 2020-03-02 4 S 0 15003 9.0945 D 355514 D Stock Options (right to buy) 5.96 2020-03-02 4 M 0 7500 0.00 D 2021-01-19 Common Stock 7500 2500 D The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $8.79 to $9.33 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All of the options were fully vested and exercisable as of March 2, 2020. /s/ Christian Formica, Attorney-in-Fact 2020-03-04